Hepatitis C News
2008
Back to Index
May
Janis and Friends Forum: Read and Comment on
EASL Coverage.
VX950 Protease
Inhibitor Telaprevir
Inhibitors & New Therapies
Advocate EASL 2008 Coverage
Latest Data From EASL 2008
New HCV Drugs Panel Discussion at EASL 2008
HALT-C Study Design Flawed
-
Pregnancy and liver disease
The role of nutrition in hepatic
encephalopathy
In Hepatitis Trends, Good News and Bad
Blood-Borne Pathogens:
A Primer
Insulin Resistance
Boceprevir Added to Pegylated Interferon/Ribavirin
Increases Sustained Response in Treatment-naive Patients and Some Prior
Non-responders
HCV Polymerase Inhibitor R1626 Produces Good Response
with Pegylated Interferon/Ribavirin and Has High Barrier to Resistance
R7128 Demonstrates Potent Anti-HCV Activity in
Combination with Pegylated Interferon/Ribavirin; Ongoing Trial to be
Expanded
-
Large HCV RNA Decrease Reduces Adverse Clinical
Outcomes, but Pegylated Interferon Maintenance Adds Little Benefit (HALT-C)
-
April
Janis and Friends Forum: Read and Comment on
EASL Coverage.
Final Results of the Phase IIIb IDEAL Study
(Individualized Dosing Efficacy vs. Flat Dosing to Assess OptimaL
PegInterferon Therapy) -
Data On Investigational Compounds Being
Co-Developed By Tibotec For The Treatment Of Chronic Hepatitis C Presented
At EASL 2008
ViroPharma and Wyeth Halt Development of HCV-796 for
Hepatitis C
Liver Diseases: A
Huge European Health Burden, But Some Trends Are Positive
Study shows positive findings in treating
patients with advanced hepatitis C
COLCHICINE VERSUS
PEG-INTERFERON ALFA 2B LONG TERM THERAPY: RESULTS OF THE 4 YEAR COPILOT
TRIAL
ALT Predicts Mortality & General Health -
RIBAVIRIN CONCENTRATION AT WEEK FOUR IS AN
INDEPENDEND PREDICTOR FOR SUSTAINED VIROLOGICAL RESPONSE AFTER TREATMENT OF
HEPATITIS C GENOTYPE 2/3 (NORDYNAMIC TRIAL)
Biolex Therapeutics Researchers Present Locteron(R)
Phase 2a Hepatitis C Trial Results at EASL Conference
Pharmasset Adds Two Cohorts to R7128
Hepatitis C Study
Vertex reports promising hepatitis C drug
results
Vertex Telaprevir HCV Protease
Inhibitor Could Be A Winner; 2.5 million untreated/undiagnosed
HCV & increased risk non-Hodgkin's Lymphoma: Hepatitis C and Non-Hodgkin
Lymphoma Among 4784 Cases and 6269 Controls From the International Lymphoma
Epidemiology Consortium -
Liver Cancer Screening Improves Survival of Patients
with Chronic Hepatitis B or C
Factors Predicting Response to Therapy for
Chronic Hepatitis C
-
Liver Gene Expression Predicts Response to Pegylated
Interferon plus Ribavirin
Combination Therapy Improves Survival Time for
Patients with Advanced Liver Cancer
Causes of Death in Individuals with Chronic HBV and/or
HCV Infection
Factors Associated with HCV Viral Load in HIV Positive
and Negative Women
HCV Advocate Newsletter, April 1,
2008
Complications of Cirrhosis -- Clinical
Insights and Implications for Practice
FYI...Warning About "Total Body" Liquid
Supplements
Vitamin C: Can too much be harmful?
FYI...Green Tea Helps Beat Superbugs, Study
Suggests
FDA Drug-Review Deadlines and Safety Problems
Communicating about Alcohol Consumption to Nonharmful
Drinkers with Hepatitis C:
Patient and Provider Perspectives.
Adult respiratory distress syndrome after
treatment with pegylated interferon alpha-2a and ribavirin.
Gastroenterologists' perceptions of need and
availability of psychiatric services for patients
with hepatitis C.
Quality-of-Life Tradeoffs for Hepatitis C Treatment:
Do Patients and Providers Agree?
Prevalence and determinants of hepatitis C
virus infection among female drug injecting sex
workers in Glasgow.
Pharma "shooting itself in the foot" over reputation
FDA Approves Label Revisions Recommending New Robetol (ribavirin)
Weight-Based Dosing Regimen: PEGINTRON PLUS WEIGHT-BASED REBETOL (ribavirin)
RESULTED IN HIGHER SVR THAN FLAT DOSING; LOW RELAPSE RATES IN PATIENTS WITH
CHRONIC HEPATITIS C. Schering Plough press release
-
New HCV Therapy Approach - Nature Publishes
Study by Santaris Pharma Scientists and Collaborators: LNA-Mediated MicroRNA
Silencing in Non-Human Primates
Hepatitis C cases expected to soar in a
decade
Liver Biopsy
Valeant Reports Promising 12-week Phase IIb Data on
Taribavirin
Rates of Hepatitis A and B Have Decreased Dramatically
since 1990, but Drop in Hepatitis C Has Leveled Off
Hepatitis C cases in New York expected to soar in a decade; 1 in 24 New
Yorkers have hepatitis C: 340,000 in NYS
March
FDA Approves New Weight-Based Dosing Regimen
for PegIntron plus Ribavirin
Alcohol, Tobacco, and Cannabis All May Promote Liver
Disease Progression in People with Chronic Hepatitis C
New data and recommendations of
antiviral therapy of chronic hepatitis B and C
U.S. hepatitis C soars in those over 45 -
HCV Death Rates 50% Underestimated
UNOS Liver Transplant Waiting List: Is it a
Scandal
Use of Different Pegylated Interferon/Ribavirin
Regimens after Rapid Virological Response Does Not Affect Sustained
Response Rate
Pathology of Chronic Hepatitis C in Children: Peds-C
Trial
Study Confirms Hepatitis C Is a Risk Factor for
Non-Hodgkin's Lymphoma
Adiponectin Level Predicts Liver Steatosis and
Response to Interferon-based Treatment for Chronic Hepatitis C
HCV Therapy: TT-033, novel RNA interference
product Oncolys and Tacere partner in hepatitis C drug development
Vertex and Tibotec Start Phase 3 Study of Telaprevir
for Treatment-Naive Genotype 1 Hepatitis C Patients
Liver patients offered hope
Nurse accused of infecting Army patients with
hepatitis
Doctors focus on liver disease linked to
obesity
Glucose >100 mg/dl Reduces Interferon/RBV SVR
-
Changing trends in hepatitis C-related mortality in the United States,
1995-2004 -
PBMC Not A Reservoir for HCV for Patients Who Clear HCV RNA, Study Reports
-
Non-invasive Markers for Liver Fibrosis in Hepatitis C
Patients with Normal ALT
Benefits of Screening for HCV Infection Based on Risk
Factors
-
Methamphetamine Promotes Hepatitis C Virus Replication
in Human Liver Cells
Liver Fibrosis Progression in HIV-HCV Coinfected
Patients Treated with Interferon plus Ribavirin
Pegylated Interferon plus Ribavirin for Patients with
HCV-related Liver Cirrhosis
Herbal medicines in acute viral
hepatitis: a ticket for more trouble
Extrahepatic Manifestations:
Vitiligo
Endoscopy Clinic Shut Down
Disability & Benefits: HCV Meets HMO
Fast Food and ALT Levels
Virological response to peg-monotherapy
improves fibrosis in Hep C
Improved 3-variable model to identify
cirrhosis
Discordance on removing patients from the
liver transplant wait list in the USA
Slow Growth Seen in Hepatitis C
Market
Hepatitis C warning for US clinic
Tysabri May Lead to Liver Injury Within a
Week After First Dose
Are patients making clinical decisions?
Surgeon Accused in Death of Patient to Get
Organs
Chronic Hepatitis C in the Hispanic/Latino Population
Living in the United States:
A Literature Review.
Nev. clinic creates hepatitis C scare
New Upper Limit Defined for Normal ALT in Adolescent
Males
-
University of Sydney researchers find new
evidence linking kava to liver damage
HCV May Directly Cause Insulin resistance
Team Identifies Human Antibodies that Prevent Hepatitis C Virus Infection in
Mouse Model -
Decreased bone mineral density after therapy with alpha interferon in
combination with ribavirin for chronic hepatitis C
-
On-treatment responses at weeks 4 and 12 can be used
to predict sustained virologic response rates in HIV HCV co-infected
patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS)
-
The way forward in HCV treatment - finding the right path: New HCV Drugs,
resistance -
We are pleased to announce Donna Fanelli MSN NP
has joined us in
answering your questions about HCV and
treatment.
Click below to Ask Donna your HCV questions
 ASK
DONNA J.C FANELLI MSN, NP
You will need to Join our
forum
with a quick registration
|
Donna J. C. Fanelli, MSN, NP-C, Medical Director of
Primary Health and Wellness Center, LLC, in Milburn,
NJ and Senior Clinical Research Coordinator of
Gastroenterology Research Associates, LLC, in Cedar
Knolls, NJ. She is certified as an Acute Care Nurse
Practitioner, an Adult Nurse Practitioner, and a
certified Sexual Assault Forensic Examiner.
We are very pleased to provide
information in this forum. The information provided
is for general educational purposes only and is
intended to help users learn about health and
diagnosed diseases. As always be sure to discuss
matters with your doctor prior to making any
important decisions regarding therapy choices. Your
doctor knows you best.
|
|
February
Liver problems: Common problems and
how to avoid them
Too Much Fast Food And Too Little Exercise
Harm The Liver
Prevalence of diabetes mellitus and insulin
resistance in patients with chronic hepatitis C:
SciClone and Sigma-Tau Report Interim Results from
Phase 3 Trial of Thymalfasin (Zadaxin) for Non-responder Hepatitis C
Patients
-
Asians with HCV Genotype 3 Do Not Respond as Well as
Caucasians to Interferon-based Therapy
Migenix Adds Higher 600 mg Celgosivir Dose of
Celgosivir in Phase II Study
HBeAg and HBV DNA Predict Outcomes of Pegylated
Interferon Therapy for Chronic Hepatitis B
How Physicians Describe Outcomes to HCV Therapy:
Prevalence and Meaning of "Cure" During
Provider-Patient In-office Discussions of HCV.
Relapse of hepatitis C virus-associated mixed
cryoglobulinemia vasculitis in patients with sustained viral response.
Prospective study of liver transplant recipients with
HCV infection: Evidence for a causal
relationship between HCV and insulin resistance.
Capecitabine for treatment of advanced hepatocellular
carcinoma
Naringenin
Compound in Grapefruit Inhibits HCV Replication in Laboratory Study
Silymarin (Milk Thistle) Does Not Affect
Hepatitis C Virus Activity or ALT Levels in HCV Patients, but Users
Report Fewer Symptoms and Better Quality of Life than Non Users
Adherence and health-related quality of life
in adolescent liver transplant recipients
Sterile Technique Violated by Another Long
Island Doctor
Making it happen: managed care considerations in
vanquishing hepatitis C.
Acute inflammatory demyelinating polyneuropathy
associated with pegylated interferon alpha 2a therapy for chronic hepatitis
C virus infection -
Enhanced Liver Fibrosis Panel Aids Testing
for Nonalcoholic Fatty Liver Disease
Heavy marijuana use linked to gum disease
Influence of Cannabis Use on Severity of
Hepatitis C Disease
Hepatitis C virus infection in the elderly:
epidemiology, natural history and management
Consecutive infections and clearances of different
hepatitis C virus genotypes in an injecting
drug user.
Transmission
of Hepatitis C Virus during Computed Tomography Scanning with Contrast
Non-Invasive Ways to Assess Liver Disease: Studies
Test Alternatives to Liver Biopsy
Vertex to Start Phase 3 Trials of HCV Protease
Inhibitor Telaprevir (VX-950)
Insulin Resistance Linked to Lower Treatment Response
in Genotype 2/3 Patients
Cure
for Cirrhosis?
Nurse admits stealing body parts of dead
Muscular exercise can cause highly
pathological liver function tests in healthy men
Patients at Risk for Liver Cancer Should Be
Screened With Ultrasound: Presented at ASCO-GI
FYI.....Liver Fat Increased in Type 2
Diabetes
SVR and Disease Progression
Adjustment of Treatment Duration Based on
Early Response
IDEAL
Trial Results
Healthwise:
Blood 101
Disability & Benefits:
Monitoring Your Health Insurance Coverage
MIGENIX To Add 600mg Daily Celgosivir Dose To
Phase II Viral Kinetics Study
You must register with clinical
care options to view the following slide shows
Source: New Management Strategies for HCV
Nonresponders and Relapsers
Learn about the causes of nonresponse and
strategies for individualizing treatment in patients with hepatitis C.
Source: Drug Resistance in Chronic Hepatitis
B: From Definitions to Management Strategies
Source: CCO Independent Conference Coverage
of the 2007 Annual Meeting of the American Association for the Study of
Liver Diseases*
January
Harm Reduction Advocates Face
Charges in San Antonio
Treatment of Hepatitis C Reduces Incidence of
Non-Hodgkin's Lymphoma
Liver Transplant Survival
CT Scans for Monitoring Liver Fibrosis
Albuferon Dose in Ongoing Trials is Lowered Due to
Safety Concerns
Frequent Cannabis Use is Associated with Liver
Fibrosis Progression in Hepatitis C Patients
Predicting sustained virological response in chronic
hepatitis C patients treated with
pegylated interferon and ribavirin using a novel highly sensitive Real-time
detection
PCR assay
Hepatitis C Virus Affects Many Organs
And Tissues, Not Just Liver
Treatment of Hepatitis C Reduces Incidence of
Non-Hodgkin’s Lymphoma
A Liver Disease Breakthrough
Proteomics prove accurate in identifying
liver cancer
Antiretroviral Drugs and Liver Injury
New Data Support FDA Warnings about Anemia
Drugs
Attention: Extra-hepatic manifestation of hepatitis C
virus infection
Hepatology Expert Discusses PegIntron vs
Pegasys IDEAL Study Findings
Combination of oxidative stress and steatosis is a
risk factor for fibrosis in alcohol-drinking patients
with chronic hepatitis C.
Hepatitis C virus infection in the elderly:
epidemiology, natural history and management.
Acute inflammatory demyelinating polyneuropathy
associated with pegylated interferon alpha 2a
therapy for chronic hepatitis C virus infection.
Severe stomatitis complicating treatment with
pegylated-interferon alpha-2a and ribavirin in an
HCV-infected patient.
IDEAL Study COMMENTARY- Doug Dieterich MD A
Healthy Dose of Curiosity Clinical trial results require careful
interpretation -
Roche responds to announcement of 'IDEAL' hepatitis C trial results
SCHERING-PLOUGH REPORTS TOP-LINE RESULTS OF THE IDEAL STUDY First Large
Study Comparing Leading Hepatitis C Therapies Shows Similar Sustained
Response Rates; Fewer Patients Relapsed Following PEGINTRON Combination
Therapy -
Chronic Marijuana Use May Increase Fibrosis for Hep C
Patients
InterMune Announces Progress on HCV Protease Inhibitor
ITMN-191
-
Stem cell therapy for chronic liver disease-choosing the right tools for the
job Commentaries -
Pfizer/Benitec to develop Hepatitis C drug
Anadys Pharmaceuticals Announces Positive
Results for ANA598 in Animal Model of Chronic Hepatitis C Virus
Infection
Cell transplantation in the treatment of liver
diseases
Moderate Exercise Yields Big Benefits
Hepatitis C genotype change after successful treatment
indicates re-infection
Growth Hormone Deficiency Common in Hepatitis C
Patients, but Improves with Interferon-based Treatment
Pegylated Interferon plus Ribavirin in the Treatment
of Chronic Hepatitis C Genotype 4
Insulin resistance and response to therapy in patients infected with chronic
hepatitis C virus genotypes 2 and 3
Psychiatric Illness and Substance Use in Veterans with
and without Hepatitis C
Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week
Combination Study for the Treatment of Chronic Hepatitis C
Psyched
Jennifer Pate, M.D., specializes in the mental health
aspects of liver disease, transplants
Natural Science
Researchers test herbal remedies
Liver-gender disruption makes men
more vulnerable to liver cancer
Ribosomal S-6 Kinase Mediates Development of
Liver Fibrosis
Variable Treatment Duration Effective for HCV
Monitoring Your Health Insurance Coverage
Deceased donor kidney and liver transplantation to
nonresident aliens in the United States
Long-Term Peginterferon Shows Promise Against
Hepatitis B in Pilot Study
Duration of Pegylated Interferon plus Ribavirin May Be
Tailored Based on Early Response
Human Genetic Variation May Protect Against HCV-related
Liver Disease Progression
Genetic Variation May Double Risk of Liver Cancer
Herbal product use by persons enrolled in the hepatitis C Antiviral
Long-Term Treatment Against Cirrhosis (HALT-C) Trial
2008 World Hepatitis Day Set for May 19
INFORMATION ON "PARTICIPATING IN CLINICAL
TRIALS" NOW AVAILABLE ON NIHSENIORHEALTH.GOV
GSK files eltrombopag for chronic ITP (thrombocytopenia) with the FDA
GB Virus C Reduced HCV-Liver Disease in HIV/HCV Coinfected
New drug 'helps to suppress hepatitis virus'
Girl Dies After Insurance Company Delays Liver
Transplant
Ursodiol Lowers Liver Enzymes in HCV Study
Study Links HCV, Tattoos
Progressing from Cirrhosis to Liver Cancer May be
Genetic
Gene Variation May Elevate Risk Of Liver Tumor In
Patients With Cirrhosis
Research Offers Promise for Cirrhosis Treatment
Weight-Based Ribavirin Dosing Equals Superior
Hepatitis C Treatment
Race Might Not Affect Liver Transplant Survival
Hepatitis C virus and the controversial role of the
interferon sensitivity determining region
in the response to interferon treatment.
Four Patients Get HCV, HIV from Organ Donor
Hepatitis C and the Health Benefits of Eating Oatmeal
Hepatitis viruses detected in four more Green Cross
blood products
Shorter Legs Linked To Liver Disease
FYI....New Link Between Stress And Disease
Susceptibility Found
Long-Term Peginterferon Shows Promise Against
Hepatitis B in Pilot Study
HCV Advocate Newsletter
Interferon Maintenance Therapy and Liver
Disease Progression
Can Mosquitoes Spread HCV?
Disability & Benefits:
Public Benefits & Residency Requirements
Top Ten Downloads of 2007
HCV New Drug Pipeline
AASLD Meeting Highlights
Researchers Show that Fibrosis can be Stopped, Cured
and Reversed
News 2007
News 2006
News
2005
News 2004
2003 Research News and Articles
HCV News Archives 2001-2002
|
